Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Astegolimab - Genentech

Next Previous
Search
Drug Profile

Astegolimab - Genentech

Alternative Names: AMG-282; Anti-ST2; MSTT 1041 A; RG 6149; RO 7187807; ST2 MAb

Latest Information Update: 17 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Genentech; Roche; University of Leicester
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-33 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease
  • Phase II Allergic asthma; Atopic dermatitis
  • Discontinued Asthma; COVID-19 pneumonia; Rhinosinusitis

Most Recent Events

  • 22 Oct 2024 Genentech completes phase I trial (In volunteers) in USA (SC) (NCT06462118)
  • 17 Jun 2024 Genentech initiates enrolment in a phase I trial (In volunteers) in USA (NCT06462118)
  • 09 May 2024 Roche plans to submit regulatory fillings in Chronic obstructive pulmonary disease, in 2025 (Roche pipeline, May 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top